

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
20 December 2001 (20.12.2001)

PCT

(10) International Publication Number
WO 01/96330 A2(51) International Patent Classification⁷: C07D 405/00

(21) International Application Number: PCT/US01/19025

(22) International Filing Date: 13 June 2001 (13.06.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/211,724 15 June 2000 (15.06.2000) US(71) Applicant: SCHERING CORPORATION [US/US];
2000 Galloping Hill Road, Kenilworth, NJ 07033-0530 (US).

(72) Inventors: CHACKALAMANNIL, Samuel; 79 Stratford Road, East Brunswick, NJ 08816 (US). CHELLIAH, Mariappan; 42K Reading Road, Edison, NJ 08817 (US). XIA, Yan; 137 Christie Street, Edison, NJ 08820 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ,

DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:


— as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations

Published:


— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.


(54) Title: THROMBIN RECEPTOR ANTAGONISTS




(I)



(c)



(a)



(b)



(d)

(57) **Abstract:** Heterocyclic-substituted compounds of formula (I) for a pharmaceutically acceptable salt thereof, are disclosed, wherein: Z is —(CH₂)_n—; (a); (b), wherein R¹⁰ is absent; or, (c) wherein R³ is absent; the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Het is an optionally substituted mono-, bi- or tri-cyclic heteroaromatic group; B is —(CH₂)_{n3}—, wherein n₃ is 0-5, —CH₂—O—, —CH₂S—, —CH₂—NR⁶—, —C(O)NR⁶—, —NR⁶C(O)—, (d), optionally substituted alkenyl or optionally substituted alkynyl; X is —O— or —NR⁶— when the double dotted line represents a single bond, or X is H, —OH or —NHR²⁰ when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C₁-C₆ alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, =NOR¹⁷, (H, H), (H, OH), (H, SH), (H, C₁-C₆ alkoxy) or (H, substituted-amino); R²² and R²³ are independently —OH, —OC(O)R³⁰, OC(O)NR³⁰R³¹, or optionally substituted alkyl, alkenyl, alkynyl, heterocycloalkyl, aryl, cycloalkyl, cycloalkenyl, carbonyl, amino, alkoxy, alkenyloxy, alkynyloxy, heterocycloalkyloxy, cycloalkyloxy, or cycloalkenyloxy; or R²² and R¹⁰, or R²³ and R¹¹, can form a carbocyclic or heterocyclic ring; and the remaining variables are as described in the specification. Also disclosed are pharmaceutical compositions containing said compounds and their use as thrombin receptor antagonists and binders to cannabinoid receptors.